ECSP099641A - Nuevos benzotiofenos y benzofuranos sustituidos en la posición 2 con heteroarilo 709 - Google Patents

Nuevos benzotiofenos y benzofuranos sustituidos en la posición 2 con heteroarilo 709

Info

Publication number
ECSP099641A
ECSP099641A EC2009009641A ECSP099641A ECSP099641A EC SP099641 A ECSP099641 A EC SP099641A EC 2009009641 A EC2009009641 A EC 2009009641A EC SP099641 A ECSP099641 A EC SP099641A EC SP099641 A ECSP099641 A EC SP099641A
Authority
EC
Ecuador
Prior art keywords
relates
benzotiophenes
heteroarilo
benzofurans
replaced
Prior art date
Application number
EC2009009641A
Other languages
English (en)
Inventor
Erwan Arzel
David Wensbo
Britt-Marie Swahn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP099641A publication Critical patent/ECSP099641A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)

Abstract

La presente invención se refiere a nuevos derivados de benzotiofeno y benzofurano sustituidos en la posición 2 con heteroarilo, sus precursores y los usos terapéuticos de tales compuestos, que poseen la fórmula estructural (Ia) anterior: y a sus sales farmacéuticamente aceptables, composiciones y métodos de empleo. Además, la invención se refiere a nuevos derivados de benzotiofeno y benzofurano sustituidos en la posición 2 con heteroarilo que son adecuados para la obtención de imágenes de depósitos de amiloide en pacientes vivos, sus composiciones, métodos de empleo y procesos para sintetizar tales compuestos. Más específicamente, la presente invención se refiere a un método de obtención de imágenes de depósitos de amiloide en el cerebro in vivo para permitir el diagnóstico de la enfermedad de Alzheimer ante mórtem así como para medir la eficacia clínica de agentes terapéuticos para tratar la enfermedad de Alzheimer.
EC2009009641A 2007-03-06 2009-09-21 Nuevos benzotiofenos y benzofuranos sustituidos en la posición 2 con heteroarilo 709 ECSP099641A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89314907P 2007-03-06 2007-03-06

Publications (1)

Publication Number Publication Date
ECSP099641A true ECSP099641A (es) 2009-10-30

Family

ID=39738510

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009641A ECSP099641A (es) 2007-03-06 2009-09-21 Nuevos benzotiofenos y benzofuranos sustituidos en la posición 2 con heteroarilo 709

Country Status (23)

Country Link
US (1) US7772256B2 (es)
EP (1) EP2132201B1 (es)
JP (1) JP5631009B2 (es)
KR (1) KR101530392B1 (es)
CN (2) CN101675042B (es)
AR (1) AR065599A1 (es)
AU (1) AU2008221668B2 (es)
BR (1) BRPI0808503B8 (es)
CA (1) CA2680157C (es)
CL (1) CL2008000645A1 (es)
CO (1) CO6220965A2 (es)
EC (1) ECSP099641A (es)
ES (1) ES2615381T3 (es)
IL (1) IL200524A0 (es)
MX (1) MX2009009469A (es)
MY (1) MY147347A (es)
NZ (1) NZ579157A (es)
PE (1) PE20090164A1 (es)
SA (1) SA08290097B1 (es)
TW (1) TW200901998A (es)
UA (1) UA98481C2 (es)
UY (1) UY30951A1 (es)
WO (1) WO2008108730A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200901998A (en) * 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
JP2011524864A (ja) 2008-05-30 2011-09-08 メルク・シャープ・エンド・ドーム・コーポレイション 新規な置換されたアザベンゾオキサゾール
JP5630867B2 (ja) 2008-08-05 2014-11-26 第一三共株式会社 イミダゾピリジン−２−オン誘導体
US8193363B2 (en) * 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
WO2011059080A1 (ja) * 2009-11-16 2011-05-19 第一三共株式会社 同位体置換されたジアミン誘導体
EP2388255A1 (en) 2010-05-11 2011-11-23 Ikerchem, S.L. Polysubstituted benzofurans and medicinal applications thereof
WO2012017891A1 (ja) * 2010-08-06 2012-02-09 国立大学法人京都大学 ピリジルベンゾフラン誘導体
KR20200118005A (ko) * 2018-02-05 2020-10-14 위니베르시떼 드 스트라스부르 통증 치료용 화합물 및 조성물
WO2021023813A1 (en) * 2019-08-06 2021-02-11 Domain Therapeutics 5-heteroaryl-pyridin-2-amine confounds as neuropeptide ff receptor antagonists

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU523040B2 (en) 1978-05-15 1982-07-08 Kanebo Limited Calcium -antagonistic composition
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
CA2034309C (en) 1990-01-22 1997-04-01 Takashi Iwaki Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus
JPH09507071A (ja) * 1993-12-21 1997-07-15 イーライ・リリー・アンド・カンパニー アミロイド原性ペプチドに関連した状態を治療又は予防する方法
US5518713A (en) 1995-02-13 1996-05-21 3V Inc. Benzoxazole derivatives, the use thereof as sunscreens and cosmetic compositions containing them
JPH11116476A (ja) 1997-10-16 1999-04-27 Sankyo Co Ltd 縮合複素環化合物
ES2536449T3 (es) 2000-08-24 2015-05-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Derivados de tioflavina para uso en diagnosis de la enfermedad de Alzheimer
WO2002051821A1 (en) 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
WO2002055496A1 (en) * 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
JP4307001B2 (ja) * 2001-03-14 2009-08-05 キヤノン株式会社 金属配位化合物、電界発光素子及び表示装置
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
US6696039B2 (en) 2001-04-23 2004-02-24 Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
WO2003045929A1 (fr) 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Derive bicyclique, procede de production de ce derive et utilisation correspondante
GB0130305D0 (en) * 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
WO2003106439A1 (ja) 2002-06-12 2003-12-24 株式会社ビーエフ研究所 アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑／びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬
TW200401194A (en) 2002-07-11 2004-01-16 Advanced Micro Devices Inc Method and apparatus for determining a processor state without interrupting processor operation
ATE425753T1 (de) * 2002-08-02 2009-04-15 Genesoft Pharmaceuticals Inc Biaryl-verbindungen mit antiinfektiver wirkung
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
US20060276433A1 (en) 2003-03-31 2006-12-07 Keiichi Kawagoe Hydrazone derivative
AU2004238508B2 (en) 2003-05-13 2009-11-19 F. Hoffmann-La Roche Ag Imidazo-benzothiazoles
WO2005003101A2 (en) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006125324A1 (en) 2005-05-27 2006-11-30 Queen's University At Kingston Treatment of protein folding disorders
CA2614116A1 (en) * 2005-07-04 2007-01-11 Novo Nordisk A/S Novel medicaments
WO2007033080A2 (en) 2005-09-12 2007-03-22 Emory University Alzheimer's disease imaging agents
EP1937260A2 (en) 2005-09-16 2008-07-02 University of Pittsburgh In-vivo and in-vitro method for detecting amyloid deposits having at least one amyloidogenic protein
SI1945622T1 (sl) 2005-10-11 2012-05-31 Univ Pittsburgh Izotopično markirane spojine benzfurana kot označevalne snovi za amiloidogenske proteine
JP4738419B2 (ja) 2005-11-30 2011-08-03 富士フイルムＲｉファーマ株式会社 アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
EP2023919A4 (en) 2006-05-08 2010-12-22 Molecular Neuroimaging Llc COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
KR20090101469A (ko) 2007-01-22 2009-09-28 아스트라제네카 아베 신규 헤테로아릴 치환된 이미다조〔１，２­ａ〕피리딘 유도체
TW200901998A (en) * 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes

Also Published As

Publication number Publication date
AU2008221668B2 (en) 2011-03-31
BRPI0808503B8 (pt) 2021-05-25
IL200524A0 (en) 2010-04-29
EP2132201B1 (en) 2016-11-16
WO2008108730A1 (en) 2008-09-12
EP2132201A4 (en) 2011-05-25
CN102617556A (zh) 2012-08-01
PE20090164A1 (es) 2009-05-03
ES2615381T3 (es) 2017-06-06
JP2010520276A (ja) 2010-06-10
CN101675042A (zh) 2010-03-17
JP5631009B2 (ja) 2014-11-26
CN101675042B (zh) 2012-06-13
CA2680157A1 (en) 2008-09-12
AR065599A1 (es) 2009-06-17
AU2008221668A1 (en) 2008-09-12
KR20090117892A (ko) 2009-11-13
UA98481C2 (en) 2012-05-25
MX2009009469A (es) 2009-09-15
BRPI0808503A2 (pt) 2014-08-19
MY147347A (en) 2012-11-30
US7772256B2 (en) 2010-08-10
EP2132201A1 (en) 2009-12-16
KR101530392B1 (ko) 2015-06-22
CO6220965A2 (es) 2010-11-19
UY30951A1 (es) 2008-10-31
US20080221149A1 (en) 2008-09-11
SA08290097B1 (ar) 2011-10-29
CA2680157C (en) 2016-04-12
RU2009133257A (ru) 2011-04-20
TW200901998A (en) 2009-01-16
BRPI0808503B1 (pt) 2020-09-29
NZ579157A (en) 2012-04-27
CL2008000645A1 (es) 2008-10-24

Similar Documents

Publication Publication Date Title
ECSP099641A (es) Nuevos benzotiofenos y benzofuranos sustituidos en la posición 2 con heteroarilo 709
ECSP088645A (es) Nuevos benzotiazoles sustituidos con heteroaril
WO2009155017A3 (en) Novel substituted azabenzoxazoles
AR114029A2 (es) Compuestos adecuados como precursores de compuestos que son útiles para obtener imágenes de depósitos amiloides, usos y procesos
UY30419A1 (es) Nuevos benzoxazoles heteroaril sustituidos
CO6290683A2 (es) Compuestos de pirido imidazolinas heterociclicas y sus composiciones como inhibidores de c-met
WO2015191506A3 (en) Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
MX2009007487A (es) Derivados de imidazo[1,2-a]piridina substituidos de heteroarilo novedosos.
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
BRPI0608387A2 (pt) compostos para o tratamento de doenças inflamatórias
CO6311099A2 (es) Derivados de benzofurano benzotiofeno benzotiazol como moduladores de fxr
ECSP12011622A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
MX342177B (es) Inhibidores de cinasa 2 de repeticion rica en leucina (lrrk2) macrociclica.
CR20130339A (es) Nuevos derivados heterocíclicos y su uso en el tratamiento de desordenes neurológicos
MY159099A (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
CR20120264A (es) Compuestos
WO2011045415A3 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
AR070395A1 (es) Derivados de 4,5-dihidro-oxazol-2-il- amina
AR079641A1 (es) Compuestos para el diagnostico por imagenes de la muerte de las celulas por apotosis
CO6501188A2 (es) Moduladores de piranil aril metil benzoquinazolina alostéricos positivos del receptos m1
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
MA34094B1 (fr) Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2
WO2010051196A8 (en) Novel substituted azabenzoxazoles
MX2017003470A (es) Inhibidores macrociclicos de cinasa lrrk2.
MX2009009113A (es) Nuevos indoles 2-heteroaril sustituidos 695.